Hematologic Neoplasms Clinical Trial
Official title:
Phase 1 Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Malignancies.
The primary objective of this study is to determine the recommended dose of CPX-351 for use in a phase 2 efficacy study in patients with leukemia. Secondarily, the study will assess the safety, serious adverse effects and how the body handles CPX-351. Preliminary evidence of antitumor activity will also be determined.
CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs
cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar
ratio. The development of CPX-351 (cytarabine:daunorubicin) Liposome Injection was based on
1) defining a synergistic ratio of the two active moieties, cytarabine and daunorubicin,
using cell-based screening assays and 2) designing a liposomal drug carrier to maintain this
ratio after intravenous administration. CPX-351 was found to be more active in in vivo
models of cancer than combinations of conventional cytarabine and daunorubicin. Both
cytarabine and daunorubicin are active chemotherapeutic agents, each approved for clinical
use in the United States for the treatment of hematological neoplasms.
CPX-351 is being developed with the hypothesis that it is superior to the currently used
regimen of cytarabine and daunorubicin in the treatment of acute leukemia. This phase I
study will determine the dose to carry forward into phase II trials.
;
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03483194 -
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03735992 -
Mind-body Medicine for Patients With Malignant Hematological Diseases
|
N/A | |
| Recruiting |
NCT04959175 -
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04275154 -
Immunological Parameters, Neurocognitive Changes, Activity, & Driving Fitness in Patients Undergoing CAR-T Cell Therapy
|
||
| Terminated |
NCT00957580 -
Trial of Pimasertib in Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
| Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
| Recruiting |
NCT00071045 -
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
|
||
| Not yet recruiting |
NCT05054231 -
Immunological Profile for Patients Treated With CAR-T Cells
|
N/A | |
| Completed |
NCT02650791 -
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study
|
Phase 3 | |
| Completed |
NCT01362179 -
National Marrow Donor Program Long-Term Donor Follow-Up
|
||
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Terminated |
NCT03648372 -
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03320915 -
Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT
|
Phase 2 | |
| Terminated |
NCT02895529 -
A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy
|
Phase 4 | |
| Active, not recruiting |
NCT03680092 -
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT03083327 -
Prophylactic Early PN in HPT/BMT
|
N/A | |
| Recruiting |
NCT03743480 -
Early Palliative Care and Hematological Cancer Patients
|
N/A | |
| Completed |
NCT02635984 -
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens
|
Phase 3 | |
| Completed |
NCT01275534 -
Symptom Experience and Self-management After Haematopoietic Stem Cell Transplantation
|
N/A |